This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Steven J. Jacobsen, MD, PhD; Slavica K. Katusic, MD; Erik J. Bergstralh, MS; George G. Klee, MD, PhD; Christopher G. Chute, MD, DrPh; Michael M. Lieber, MD
Mayo Clinic and Mayo Foundation Rochester, Minn

Joseph E. Oesterling, MD
University of Michigan Ann Arbor

JAMA. 1996;275(15):1155-1156.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We agree with the comments from Drs Rhoads and Mills regarding the lack of data in our article that demonstrate a reduction in morbidity and mortality from prostate cancer. However, their assertion that the transient increase in incidence of prostate caner will not be short lived is perhaps too globally stated. The duration of the increase is a function of the incidence and prevalence of cancer and it also depends on the degree of penetration of screening programs. In Olmsted County, Minnesota, where the rates of serum PSA testing have reached 50% of the population of men in their 60s, the transient increase will be much shorter lived than in areas where only 10% to 20% of the population is screened each year.

Rhoads and Mills are also correct in focusing on mortality as one of the ultimate measures of efficacy of the screening program. We hope that . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?